Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin - Summary - MDSpire
Conference News

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

Share

Colorectal cancer is the third most commonly diagnosed cancer in the U.S., with an estimated 154,270 new cases and 53,000 deaths in 2025, as reported by the American Cancer Society. Recent research suggests that GLP-1 receptor agonists (GLP-1RAs), commonly used for diabetes and obesity, may significantly reduce colorectal cancer risk compared to low-dose aspirin. In a large-scale study presented at the 2026 ASCO Gastrointestinal Cancers Symposium, users of GLP-1RAs were 36% less likely to develop colorectal cancer than those taking aspirin, with differences noted in the safety profile of both medications.

Original Source(s)

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

  • by Jo Cavallo

  • April 3, 2026

Related Content

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) was issued full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval now includes efficacy, safe...

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

Turning Proteins into DNA for Ultra-Sensitive Sequencing

Stanford researchers repurpose DNA sequencing technology to read proteins at single-molecule resolution, complementing – and potentially surpassing – mass spectrometry

  • April 2, 2026

  • 2 min